drugset / Trial / NCT00004177
Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer
Phase 1/2
Completed
15 enrolled
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by therapy used to kill tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of radiolabeled monoclonal antibody plus peripheral stem cell transplantation in treating patients who have refractory or recurrent ovarian epithelial cancer.
Timeline
- Start
- 1999-08
- Primary completion
- 2002-05
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YTTRIUM Y 90 LABETUZUMAB | Monoclonal antibody | — | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | — | Subcutaneous |